Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 28
Filter
Add more filters










Publication year range
1.
Neuropathol Appl Neurobiol ; 44(4): 391-403, 2018 06.
Article in English | MEDLINE | ID: mdl-28953319

ABSTRACT

AIM: Vanishing White Matter (VWM) is a devastating leucoencephalopathy without effective treatment options. Patients have mutations in the EIF2B1-5 genes, encoding the five subunits of eIF2B, a guanine exchange factor that is an important regulator of protein translation. We recently developed mouse models for VWM that replicate the human disease. To study disease improvement after treatment in these mice, it is essential to have sensitive biomarkers related to disease stage. The Bergmann glia of the cerebellum, an astrocytic subpopulation, translocate into the molecular layer in symptomatic VWM mice and patients. This study looked at the prospects of using Bergmann glia pathology as an objective disease marker for VWM. METHODS: We defined a new quantitative measurement of Bergmann glia pathology in the cerebellum of VWM mice and patients. To test the sensitivity of this new marker for improvement, VWM mutant mice received long-term treatment with Guanabenz, an FDA-approved anti-hypertensive agent affecting eIF2B activity. RESULTS: Bergmann glia translocation was significantly higher in symptomatic VWM mice and VWM patients than in controls and worsened over the disease course. Both Bergmann glia pathology and cerebellar myelin pathology improved with Guanabenz treatment in mice, showing that Bergmann glia translocation is a sensitive measurement for improvement. CONCLUSIONS: Bergmann glia translocation can be used to objectively assess effects of treatment in VWM mice. Future treatment strategies involving compounds regulating eIF2 phosphorylation might benefit VWM patients.


Subject(s)
Adrenergic alpha-2 Receptor Agonists/therapeutic use , Astrocytes/pathology , Guanabenz/therapeutic use , Leukoencephalopathies/pathology , Animals , Biomarkers , Disease Models, Animal , Disease Progression , Leukoencephalopathies/drug therapy , Mice , Phosphorylation , Treatment Outcome
2.
Stem Cell Rev Rep ; 13(5): 659-669, 2017 Oct.
Article in English | MEDLINE | ID: mdl-28730556

ABSTRACT

In age-related macular degeneration (AMD) the retinal pigment epithelium (RPE) deteriorates, leading to photoreceptor decay and severe vision loss. New therapeutic strategies aim at RPE replacement by transplantation of pluripotent stem cell (PSC)-derived RPE. Several protocols to generate RPE have been developed where appearance of pigmentation is commonly used as indicator of RPE differentiation and maturation. It is, however, unclear how different pigmentation stages reflect developmental stages and functionality of PSC-derived RPE cells. We generated human embryonic stem cell-derived RPE (hESC-RPE) cells and investigated their gene expression profiles at early pigmentation (EP) and late pigmentation (LP) stages. In addition, we compared the hESC-RPE samples with human endogenous RPE. We used a common reference design microarray (44 K). Our analysis showed that maturing hESC-RPE, upon acquiring pigmentation, expresses markers specific for human RPE. Interestingly, our analysis revealed that EP and LP hESC-RPE do not differ much in gene expression. Our data further showed that pigmented hESC-RPE has a significant lower expression than human endogenous RPE in the visual cycle and oxidative stress pathways. In contrast, we observed a significantly higher expression of pathways related to the process adhesion-to-polarity model that is typical of developing epithelial cells. We conclude that, in vitro, the first appearance of pigmentation hallmarks differentiated RPE. However, further increase in pigmentation does not result in much significant gene expression changes and does not add important RPE functionalities. Consequently, our results suggest that the time span for obtaining differentiated hESC-RPE cells, that are suitable for transplantation, may be greatly reduced.


Subject(s)
Human Embryonic Stem Cells/metabolism , Pigmentation/genetics , Pluripotent Stem Cells/metabolism , Retinal Pigment Epithelium/metabolism , Transcription Factors/genetics , Biomarkers/metabolism , Cell Adhesion , Cell Differentiation , Cell Line , Cell Polarity , Gene Expression , Gene Expression Profiling , Human Embryonic Stem Cells/cytology , Humans , Pluripotent Stem Cells/cytology , Retinal Pigment Epithelium/cytology , Signal Transduction , Tissue Array Analysis , Transcription Factors/metabolism
4.
Mol Psychiatry ; 21(9): 1167-79, 2016 09.
Article in English | MEDLINE | ID: mdl-27240529

ABSTRACT

Major programs in psychiatric genetics have identified >150 risk loci for psychiatric disorders. These loci converge on a small number of functional pathways, which span conventional diagnostic criteria, suggesting a partly common biology underlying schizophrenia, autism and other psychiatric disorders. Nevertheless, the cellular phenotypes that capture the fundamental features of psychiatric disorders have not yet been determined. Recent advances in genetics and stem cell biology offer new prospects for cell-based modeling of psychiatric disorders. The advent of cell reprogramming and induced pluripotent stem cells (iPSC) provides an opportunity to translate genetic findings into patient-specific in vitro models. iPSC technology is less than a decade old but holds great promise for bridging the gaps between patients, genetics and biology. Despite many obvious advantages, iPSC studies still present multiple challenges. In this expert review, we critically review the challenges for modeling of psychiatric disorders, potential solutions and how iPSC technology can be used to develop an analytical framework for the evaluation and therapeutic manipulation of fundamental disease processes.


Subject(s)
Mental Disorders/genetics , Mental Disorders/metabolism , Models, Biological , Autistic Disorder/metabolism , Cellular Reprogramming , Genomics , Humans , Induced Pluripotent Stem Cells/metabolism , Schizophrenia/metabolism
5.
Neuroscience ; 129(3): 593-601, 2004.
Article in English | MEDLINE | ID: mdl-15541881

ABSTRACT

Various chronic stress paradigms decrease new cell proliferation in the hippocampal dentate gyrus, yet the exact underlying mechanism is still unclear. In the first gap (G1) phase of the cell cycle, both stimulatory and inhibitory signals derived from the extracellular environment converge. Corticosteroids, which increase during stress and are well-known anti-mitotics, cause cells in vitro to arrest in the G1 phase. Following 3 weeks of unpredictable stress, we therefore expected a change in protein expression of various important G1 cell cycle regulators in the adult rat subgranular zone. Using quantitative immunocytochemistry, we show that particularly cyclin-dependent kinase inhibitor p27Kip1 expression is significantly increased. In addition, 3 weeks of recovery after stress normalized the numbers of p27Kip1-expressing cells, consistent with the recovered adult cell proliferation in these animals. P27Kip1-positive cells do not overlap with GFAP-staining and only to a limited extent with Ki-67-expressing cells. Numbers of cyclin E- and cyclin D1-expressing cells did not change after chronic stress. These results indicate that chronic stress causes cycling cells in the adult hippocampus to arrest in G1, thereby providing more mechanistic insight in the stress-induced decrease in cell proliferation.


Subject(s)
Cell Cycle Proteins/metabolism , Dentate Gyrus/metabolism , G1 Phase/physiology , Gene Expression Regulation/physiology , Stress, Physiological/metabolism , Tumor Suppressor Proteins/metabolism , Animals , Behavior, Animal , Cell Count/methods , Cold Temperature/adverse effects , Cyclin D1/metabolism , Cyclin E/metabolism , Cyclin-Dependent Kinase Inhibitor p27 , Dentate Gyrus/cytology , Glial Fibrillary Acidic Protein/metabolism , Immobilization/methods , Immunohistochemistry/methods , Ki-67 Antigen/metabolism , Male , Random Allocation , Rats , Rats, Wistar , Statistics, Nonparametric , Stress, Physiological/physiopathology , Time Factors
6.
Nature ; 403(6772): 836-7, 2000 Feb 24.
Article in English | MEDLINE | ID: mdl-10706262
7.
Phys Rev B Condens Matter ; 53(13): 8257-8261, 1996 Apr 01.
Article in English | MEDLINE | ID: mdl-9982322
8.
Phys Rev Lett ; 76(8): 1284-1287, 1996 Feb 19.
Article in English | MEDLINE | ID: mdl-10061682
11.
Phys Rev Lett ; 72(14): 2303, 1994 Apr 04.
Article in English | MEDLINE | ID: mdl-10055841
14.
Phys Rev Lett ; 70(13): 1944-1947, 1993 Mar 29.
Article in English | MEDLINE | ID: mdl-10053426
15.
Phys Rev B Condens Matter ; 47(8): 4174-4180, 1993 Feb 15.
Article in English | MEDLINE | ID: mdl-10006559
16.
Phys Rev B Condens Matter ; 45(12): 6376-6382, 1992 Mar 15.
Article in English | MEDLINE | ID: mdl-10000401
17.
Phys Rev B Condens Matter ; 45(12): 6534-6542, 1992 Mar 15.
Article in English | MEDLINE | ID: mdl-10000414
18.
Phys Rev Lett ; 66(19): 2480-2483, 1991 May 13.
Article in English | MEDLINE | ID: mdl-10043499
19.
Phys Rev B Condens Matter ; 41(10): 7028-7041, 1990 Apr 01.
Article in English | MEDLINE | ID: mdl-9992960
20.
Phys Rev Lett ; 64(10): 1178, 1990 Mar 05.
Article in English | MEDLINE | ID: mdl-10041319
SELECTION OF CITATIONS
SEARCH DETAIL
...